InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
0.9260
-0.0076 (-0.81%)
Feb 26, 2026, 3:10 PM EST - Market open
InflaRx Employees
InflaRx had 74 employees as of December 31, 2024. The number of employees increased by 12 or 18.97% compared to the previous year.
Employees
74
Change (1Y)
12
Growth (1Y)
18.97%
Revenue / Employee
$996
Profits / Employee
-$635,850
Market Cap
62.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 74 | 12 | 18.97% |
| Dec 31, 2023 | 62 | 18 | 40.41% |
| Dec 31, 2022 | 44 | -12 | -20.75% |
| Dec 31, 2021 | 56 | 9 | 18.18% |
| Dec 31, 2020 | 47 | 4 | 8.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| Metagenomi Therapeutics | 124 |
| MindWalk Holdings | 102 |
| ImmuCell | 84 |
| PMV Pharmaceuticals | 47 |
| Mereo BioPharma Group | 36 |
| Q32 Bio | 26 |
| Instil Bio | 14 |
IFRX News
- 7 hours ago - InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Participation in February Investor Conferences - GlobeNewsWire
- 7 weeks ago - InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewsWire
- 2 months ago - InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - GlobeNewsWire
- 2 months ago - InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 - GlobeNewsWire
- 3 months ago - InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa Transcript - Seeking Alpha
- 3 months ago - InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) - GlobeNewsWire
- 3 months ago - InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria - GlobeNewsWire